World Cardiovascular Disease Diagnostics Markets

World Cardiovascular Disease Diagnostics Markets

This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in Millions of US$. The major product segments analyzed are In Vitro Diagnostics, and In Vivo Diagnostics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 72 companies including many key and niche players worldwide such as Abbott Diagnostics, Biosite, Inc., Cambridge Heart, Inc., Cholestech Corp., Dade Behring, Inc., EP Medsystems, GE HealthCare, Liposcience, Inc., Philips Medical Systems, Roche Diagnostics, and Siemens Medical Solutions. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
Market Analysis II-1
Analysis by Product Type II-1
Cardiology Diagnostic Imaging: Future Outlook II-1
Heart -Facts and Figures II-2
Swift Growth in Cardiovascular Disease Devices Market II-2
Cardiovascular Diseases Damaging Human Health II-3
Mounting Healthcare Costs- “A Real Concern for Economies” II-3
Competition in the Cardiac Diagnostics Market II-3
Market Trends II-3
Advancement of POC Testing Propels Cardiovascular Diagnostics
Market II-3
Demand on Rise for POC Cardiac Markers II-4
Minimal Invasive Procedure Hogs the Limelight of
Cardiovascular Treatment II-4
Advancements in Alternate-Site Coagulation Monitoring II-4
Novel Imaging Techniques Boost In vivo Diagnostic Market II-5
Strong Demand for Risk Assessment Markers II-5
New Technologies Bring Diagnostics Closer to Patients II-5
Trends Cited in the Imaging Technologies Market II-6
CT Scanners II-6
MRI II-7
Move Towards Efficient Patient Data Management II-7

2. CVD - Cause and Risk Factors II-8
CVD - Global Facts II-8
Atherosclerosis - Leading Cause for CVD II-8
Risk Factors II-8
Irreversible Risk Factors II-8
Increasing age II-8
Sex (gender) II-9
Heredity (including Race) II-9
Risk Factors that can be controlled II-9
Tobacco Smoke II-9
High Blood Cholesterol II-9
LDL Cholesterol II-9
HDL Cholesterol II-10
Triglyceride levels II-10
Hypercholesterolemia - Conditions Associated with
Cholesterol Level II-11
High Blood Pressure II-11
BP - Leading Cause of Cardiovascular Disease in Young Adults II-11
Physical Inactivity II-11
Obesity and Overweight II-12
Diabetes Mellitus II-12
Cardiovascular Disease and Homocysteine Levels II-12
Measures for Reducing Cardiovascular Diseases II-13

3. Cardiovascular Disease and Conditions II-14
Angina Pectoris II-14
Arrhythmias II-14
Sudden Cardiac Death (SCD) II-14
Stroke II-14
Congestive Heart Failure II-15
Cardiovascular Disease Involving Transplant Patients II-15

4. Diagnostic Tests for Cardiovascular Diseases II-16
In-Vitro Cardiovascular Diagnostics II-16
Cholesterol Testing II-16
Use of Markers II-16
Creatine Kinase MB II-16
Troponin T and Troponin I II-17
C-reactive Protein II-17
Plasminogen Activator Inhibitor-1 II-17
D-Dimer II-18
Thrombus Precursor Protein II-18
Other Cardiac Markers II-18
Demand Grows for Risk Assessment Markers II-18
A Step Forward in Cardiovascular Risk Assessment II-18
In Vivo Diagnostic Tests II-19
Computer Imaging / Tomography II-19
Electron Beam Computer Tomography (EBCT) II-19
Appropriate Conditions for EBCT Diagnosis II-19
Cardiac Positron Emission Tomography (PET) II-20
Digital Cardiac Angiography/ Digital Subtraction Angiography II-20
Magnetic Resonance Imaging (MRI) II-20
Single Photon Emission Computed Tomography (SPECT) II-21
Echocardiography II-21
Different Types of Echo-techniques II-22
M-mode (Motion mode, One-dimensional) II-22
Two-Dimensional (Cross-sectional) II-22
Stress Echocardiogram (Stress Echo) II-22
Transesophageal Echocardiogram (TEE) II-22
Risks II-23
Ultrasound Tests II-23
Doppler Ultrasound II-23
Intravascular Ultrasound II-23
Working II-23
Comparative Facts Related to Definitive Diagnosis of
Cardiovascular Disease II-24
Nuclear Cardiology Tests II-24
Applications II-25
Types of Nuclear Cardiology Tests II-25
Myocardial Perfusion Imaging II-25
Applications II-25
Risks II-25
Ventricular Function Test II-26
Types: II-26
Testing Cardiac Stress II-26
Cardio Vascular Disease Diagnostics Tests in the Pipeline II-26
Aderis MRE-0470 II-26
CardioMEMS Novel Technology II-26
Technology Platform II-27

5. Product Launches and Developments II-28
Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner II-28
Royal Philips Launches Live 3D Transesophageal Echocardiogram
Probe II-28
GE Healthcare Launches Vivid e Ultrasound Systems II-28
Cardionetics Launches ECG Monitor for 24-Hour Real-Time
Cardiac Diagnosis II-28
Siemens Launches Imaging Release for the ACUSON Sequoia Platform II-28
GE Healthcare Launches Version 2.0 of Centricity Cardiology
CA1000 II-29
GE Healthcare Introduces New Capabilities to CardioSoft
Diagnostic Software II-29
GE Healthcare’s Lightspeed VCT Offers Imaging at 70% Lower
Exposure II-29
Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker
System (Outside US) II-29
Royal Philips Launches New Imaging Tool for Complex Cardiac
Arrhythmias II-30
Siemens Medical Introduces syngo® US, New Echocardiography
Solution. II-30
Dade Behring Introduces CardioPhase® hsCRP Test for Multiple
Testing Platforms. II-30
Shimadzu Launches Two Models in Angiographic Imaging II-30
Omron Healthcare Introduces Non Invasive Vascular Profiling
System II-31
Abbott Launches XIENCE V, New Coronary Stent System II-31
Siemens Medical Introduces Acuson AcuNav 8F, an Advanced
Ultrasound Catheter II-31
BioMérieux Introduces High Performance VIDAS Troponin I Ultra II-31
Siemens Launches Acuson X300 Ultrasound Platform II-32
Siemens Releases Web-Enabled CT II-32
GE Introduces Latest Electrocardiograph Device, MAC 3500 II-32
GE Emphasizes on the Striking Features of New Vivid 7
Dimension ’06 II-33
GE Launches Latest Innova Digital Flat Panel Biplane Imaging
Devices II-33
Medtronic Introduces Latest Range of Implantable Cardiac
Defibrillators II-33
Philips Introduces Web Based Cardiac Tools II-33
Siemens Showcases Solutions for Cardiac Problems Through
Molecular Imaging II-34
Siemens Presents Advancements in Echocardiography II-34
Siemens Debuts syngo BEAT II-34
Siemens Combines syngo® Dynamics with Soarian® for
Cardiovascular EPR II-34
GE Healthcare Unveils CardIQ Fusion II-35
GE Introduces VCT II-35
GE Unveils Dynamic VUE II-35
GE Launches CardIQ Xpress II-35
GE Presents the Ventri for Cardiac Imaging II-35
GE Introduces High Definition Magnetic Resonance System II-35
Dade Behring Unveils CardioPhase(R) hsCRP Test II-36
Siemens Launches Encompass III on C512 Ultrasound Platform II-36
Siemens Launches Four New CT Clinical Engines II-36
Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool II-36
Corgenix Introduces Predictive Cardiovascular Diagnostic Kit,
AtherOx™ II-36
Philips Introduces HD11 XE Cardiology Ultrasound System II-37
Siemens Introduces Biplane FD Cardiology System II-37
Siemens Introduces Syngo Circulation Software for CT Tomography II-37
Siemens Introduces SOMATOM Definition for Cardiac Imaging II-37
Dade Behring Unveils Homocysteine Test on BN(TM) Systems II-37
Roche Unveils Cardiac pro-BNP Test II-38
Philips Introduces HD11 XE II-38
Corgenix Unveils AtherOx(TM) II-38
GE Healthcare Unveils Breakthrough Imaging Technology II-38
Philips Launches Products to Detect Heart Problems II-39
Philips Unveils Computed Tomography and EP Planning package II-39
Philips Widens Magnetic Resonance Kitty II-39
New Cardiac Monitoring Products from Philips II-39
Siemens Launches Image-Arena II-39
Siemens Announces New Procam-Calculator Combined with CT
Examination II-40
Siemens Medical Solutions Launches Axiom Artis dTA II-40
GE Healthcare Unveils Vivid i II-40
GE Healthcare Presents Fully Integrated 4D Cardiovascular
Ultrasound System II-41
GE Healthcare Debuts New Imaging System II-41
New Discovery PET/CT Systems from GE Healthcare II-41
SonoSite Presents SonoCalc IMT Software II-41
Dade Behring Introduces High Sensitivity Troponin I Assay II-42
Biosite Unveils New Diagnostic Test II-42
MDS Diagnostic Services Unveils New Test to Prevent Heart Disease II-42
diaDexus Develops PLAC Test II-43
Siemens Introduces New Nuclear Cardiology Imaging System II-43
Roche Diagnostics Receives U.S. Clearance and European CE Mark II-43
Camtronics Unveils Cardiovascular Screening Software II-43
Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment
Test II-44

6. Recent Industry Activity II-45
Siemens Medical acquires Dade Behring II-45
Inverness Medical Innovations Acquires Cholestech II-45
Acrongenomics, Pearson and Molecular Enter into Joint Venture II-45
Cholestech Teams Up with Onsite Health Diagnostics II-46
Lipomics to Collaborate with Agilent Technologies to Develop
Diagnostic Tests. II-46
Transgenomic and Fiuotecnica Renew Collaboration Agreement II-46
Alteon and BioRap Technologies Enter into an Agreement II-46
IM Medical Acquires New Technology for Detecting
Cardiovascular Diseases II-47
Medtronic Establishes New Business Entity II-47
Siemens Medical Acquires Bayer Healthcare’s Diagnostics Unit II-47
Spacelabs Acquires Ferraris’ Cardiac Unit II-47
Global Immune Takes over Primedical International II-48
Siemens Acquires Diagnostics Products II-48
Cholestech and Life Line Enter into Collaboration II-48
LipoScience Signs an Agreement with ARUP II-48
Philips Acquires Witt Biomedical II-49
CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray II-49
Biosense Enters into Strategic Partnership with Siemens
Medical Solutions II-49
Dade Behring Approved the Use of FSAP Antibodies by American
Diagnostica II-49
Abbott Receives Non-exclusive Sublicense for Diagnostic Use of
PIGF II-50
Nanogen Acquires Spectral’s Cardiac Test Division II-50
Varian Enters into Alliance with LipoScience to Jointly
Develop NMR System II-50
Cardiac Services Professionals Establishes eCardio Diagnostics II-50
Response Biomedical Wins Nonexclusive License Rights for NT-
proBNP and Troponin T II-51
Biomerieux gains Nonexclusive License for NT-proBNP II-51
Philips and PMI Ink an Agreement for Outpatient Facility II-51
LipoScience Enters into an Agreement with LabCorp II-51
Abbott and Cleveland Clinic to Co-develop Myeloperoxidase
Cardiac Test II-51
Abbott Receives 510(k) Clearance from FDA for Myoglobin Test II-52
FDA Clears Additional Claim for Biosite’s Triage(R) BNP Test II-52
Biosite Inks an Agreement with University of Mainz II-52
Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay II-52
Nanogen Acquires SYN•X Pharma II-52
GE Takes Over Amersham Plc II-52
St. Jude Medical Acquires Irvine Biomedical and Epicor II-53
SonoSite Snaps Up SonoMetric II-53
CardioDynamics Purchases Vermed II-53
Philips and EP MedSystems Announce an Alliance Involving
Electrophysiology Solutions II-53
Toshiba and ViTAL Enters into an Alliance with Johns Hopkins
University School of Medicine II-53
Response Biomedical Collaborates with Shionogi II-53
Terumo Signs Agreement with Spencer Technologies II-54
Spectral Diagnostics Announces Agreement with NGC Medical II-54
Philips Signs Agreement with Fletcher Allen Health Care II-54
Spectral Diagnostics Enters into an Agreement with Cardinal
Health II-54
Siemens Signs Agreement with MediGuide II-54
Biosite Enters into Agreement with DMI BioSciences II-55
Cambridge Heart Enters into Agreement with Del Mar Reynolds II-55
Cholestech Enters into an Agreement with Itamar Medical II-55
Siemens Enters into a Contract with HiPGraphics II-55
Abbott Announces US Clearance for Axis-Shield’s BNP Test for
Use on AxSYM II-55
Cholestech Announces FDA 510(k) Approval for hs-CRP Test II-55
Dade Behring Bags FDA Clearance NT-proBNP Test II-56
Dade Behring Receives FDA Clearance for N High Sensitivity CRP
Assay II-56
EP-4 Computerized Cardiac Stimulator Bags FDA Approval II-56
Biosite Adds two new offices II-56
Bayer Diagnostics Enhances BNP Assay Offering Globally II-56
EP MedSystems Garners CE Approval for ALERT Deflectable CS
Catheter in Europe II-57
Cambridge Heart Inc and Quinton Cardiology Systems Renew Pact II-57
EPIX and Schering AG Extends Collaboration Agreement II-57
Siemens Ultrasound and TomTec Imaging Systems Announces Agreement II-57
FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative
Cardiovascular Devices II-58
Beckman Coulter Enters into Agreement with Biosite II-58
Dade Behring Garners Non-exclusive Rights for a Key Cardiac
Marker II-58
Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc
to Develop CardioGen-82® II-58
New Lab Test from diaDexus Receives FDA Clearance II-59
Hypertension Diagnostics Receives SDA Approval in China II-59

7. Focus on Select Global Players II-60
Abbott Diagnostics (USA) II-60
Biosite Inc. (USA) II-60
Cambridge Heart, Inc. (USA) II-60
Cholestech Corp. (USA) II-61
EP Medsystems (USA) II-61
GE HealthCare (USA) II-61
Liposcience, Inc. (USA) II-62
Philips Medical Systems (USA) II-62
Roche Diagnostics (Switzerland) II-62
Siemens Medical Solutions (Germany) II-63

8. Global Market Perspective II-64
Table 1: World Recent Past, Current & Future Market Analysis
for Cardiovascular Disease Diagnostics by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-64

Table 2: World Long-term Projections for Cardiovascular
Disease Diagnostics by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-65

Table 3: World 10-Year Perspective for Cardiovascular Disease
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets for
Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) II-66

Table 4: World Recent Past, Current & Future Market Analysis
for Cardiovascular In Vitro Diagnostics by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-67

Table 5: World Long-term Projections for Cardiovascular In
Vitro Diagnostics by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-68

Table 6: World 10-Year Perspective for Cardiovascular In Vitro
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets for
Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) II-69

Table 7: World Recent Past, Current & Future Market Analysis
for Cardiovascular In Vivo Diagnostics by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-70

Table 8: World Long-term Projections for Cardiovascular In
Vivo Diagnostics by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-71

Table 9: World 10-Year Perspective for Cardiovascular In Vivo
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets for
Years 2000, 2007 & 2010 (includes corresponding Graph/Chart) II-72


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Startling Facts Related to Cardiovascular Disease in the US III-1
Cardio Vascular Disease (CVD) - An Overview III-1
Table 10: Prevalence of Cardiovascular Disease in the US in
the Recent Past (2004) (includes corresponding Graph/Chart) III-2

Table 11: Percentage Breakdown of Deaths from
Cardiovascular Diseases in the USin the Recent Past (2004)
(includes corresponding Graph/Chart) III-2

Table 12: Prevalence of Cardiovascular Diseases among
Americans by Age (Age 20 and Older) and Sex in the Recent
Past (2004) (includes corresponding Graph/Chart) III-3

Table 13: A Factoid of CHD and MI in the US in the Recent
Past (2003) (In Million) III-3
Startling facts related to Stroke in US III-3
Table 14: A Factoid of Stroke in the US in the Recent Past
(2003) (In Million) III-4
Incidence of Coronary Heart Disease III-4
Mortality rate of CHD III-4
Table 15: Annual Number of Americans Having Diagnosed Heart
Attack by Age and Sex in the Recent Past (2004) (includes
corresponding Graph/Chart) III-5

Table 16: Prevalence of CHD by Age and Sex in the Recent
Past (2004) (In % population) (includes corresponding
Graph/Chart) III-5
Arrhythmias III-5
CAD Diagnostics III-6
PVD Diagnostics III-6
Medicare Reimbursement Set for CPT Code 83704 III-6
Competitive Glance III-6
Point-of-Care (POC) Diagnostic Market in the US III-6
Table 17: Leading Players in the US POC Cardiac Market
(2004) - Percentage Breakdown by Value Sales for Biosite,
Dade Behring, Spectral Diagnostics, Roche and Others
(includes corresponding Graph/Chart) III-7
Review of Major Players III-7
Abbott Diagnostics III-7
Biosite Inc III-7
Cambridge Heart, Inc III-8
Cholestech Corp III-8
EP Medsystems III-9
Liposcience, Inc. III-9
Philips Medical Systems III-9
Product Launches/Developments III-10
Strategic Developments III-21
B.Market Analytics III-31
Table 18: US Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-31

Table 19: US Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-32

Table 20: US 10-Year Perspective for Cardiovascular Disease
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for In Vitro Diagnostics and In Vivo
Diagnostics Markets for 2000, 2007 & 2010 III-32

2. Canada III-33
A.Market Analysis III-33
Product Launch III-33
Strategic Developments III-33
B.Market Analytics III-35
Table 21: Canadian Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Product Segment -
In Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-35

Table 22: Canadian Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-35

Table 23: Canadian 10-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2000, 2007 & 2010 III-36

3. Japan III-37
A.Market Analysis III-37
Strategic Developments III-37
B.Market Analytics III-37
Table 24: Japanese Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Product Segment -
In Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-37

Table 25: Japanese Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-38

Table 26: Japanese 10-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2000, 2007 & 2010 III-38

4. Europe III-39
A.Market Analysis III-39
European Union Cardiovascular Diseases Fact Sheet III-39
In Vivo Diagnostics - Leading Segment III-39
Germany - The Largest European Market III-39
Product Launches III-40
B.Market Analytics III-42
Table 27: European Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Geographic Region
- France, Germany, Italy, UK, Spain, Russia & Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-42

Table 28: European Long-term Projections for Cardiovascular
Disease Diagnostics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia & Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-43

Table 29: European Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Product Segment -
In Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-43

Table 30: European Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-44

Table 31: European 10-Year Perspective for Cardiovascular
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK, Spain, Russia &
Rest of Europe Markets for Years 2000, 2007 & 2010 (includes
corresponding Graph/Chart) III-44

Table 32: European 10-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2000, 2007 & 2010 III-45

4a. France III-46
A.Market Analysis III-46
Strategic Development III-46
B.Market Analytics III-46
Table 33: French Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-46

Table 34: French Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-47

Table 35: French 10-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2000, 2007 & 2010 III-47

4b. Germany III-48
A.Market Analysis III-48
Siemens Medical Solutions - A Major Player III-48
Product Launches III-48
Strategic Developments III-52
B.Market Analytics III-53
Table 36: German Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-53

Table 37: German Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-53

Table 38: German 10-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2000, 2007 & 2010 III-54

4c. Italy III-55
A.Market Analysis III-55
Strategic Developments. III-55
B.Market Analytics III-56
Table 39: Italian Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-56

Table 40: Italian Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-56

Table 41: Italian 10-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2000, 2007 & 2010 III-57

4d. The United Kingdom III-58
A.Market Analysis III-58
UK Cardiovascular Diseases Fact Sheet III-58
Key Player Review III-59
GE HealthCare III-59
B.Market Analytics III-59
Table 42: UK Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-59

Table 43: UK Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-60

Table 44: UK 10-Year Perspective for Cardiovascular Disease
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for In Vitro Diagnostics and In Vivo
Diagnostics Markets for 2000, 2007 & 2010 III-60

4e. Spain III-61
Market Analysis III-61
Table 45: Spanish Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-61

Table 46: Spanish Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-62

Table 47: Spanish 10-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2000, 2007 & 2010 III-62

4f. Russia III-63
Market Analysis III-63
Table 48: Russian Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-63

Table 49: Russian Long-term Projections for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-64

Table 50: Russian 10-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2000, 2007 & 2010 III-64

4g. Rest of Europe III-65
A.Market Analysis III-65
Roche Diagnostics - A Key Swiss Player III-65
B.Market Analytics III-66
Table 51: Rest of Europe Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-66

Table 52: Rest of Europe Long-term Projections for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-66

Table 53: Rest of Europe 10-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 &
2010 III-67

5. Asia Pacific III-68
A.Market Analysis III-68
Cardiovascular Market in Asia-Pacific III-68
China III-68
Cardiovascular Disease Patients Overview III-68
Treatment Providers and Hospitals Overview III-69
Hospitals III-69
Table 54: Cardiovascular Special Treatment Hospitals in
China: 1991-2011(In numbers) (includes corresponding
Graph/Chart) III-69
Chinese Cardiovascular Disease Treatment as a Part of
Overall Health Care Industry III-69
Table 55: Cardiovascular Diseases Treatment inChina:
1991-2011(In US$ million) (includes corresponding
Graph/Chart) III-70
Strategic Developments III-70
B.Market Analytics III-72
Table 56: Asia-Pacific Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-72

Table 57: Asia-Pacific Long-term Projections for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-72

Table 58: Asia-Pacific 10-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 &
2010 III-73

6. The Middle East III-74
Market Analysis III-74
Table 59: Middle East Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-74

Table 60: Middle East Long-term Projections for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-75

Table 61: Middle East 10-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2000, 2007 & 2010 III-75

7. Latin America III-76
A.Market Analysis III-76
Strategic Development III-76
B.Market Analytics III-77
Table 62: Latin American Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-77

Table 63: Middle East Long-term Projections for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-77

Table 64: Latin American 10-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2000, 2007 &
2010 III-78


IV. COMPETITIVE LANDSCAPE